INDIANAPOLIS: Pharmaceutical firm Eli Lilly and Company is strengthening its communications efforts for its clinical trial diversity strategy. The American Cancer Society reported earlier this year that only 17% of clinical trial participants are minorities.

The company released an observational study earlier this week reporting that minority participation increased by 43% after a number of enhancements were made to the process.

Nearly three years ago, Eli Lilly began pushing for increased enrollment of diverse populations in clinical trials, ...